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Editorial
Pernicious and Threatening Plasmodium vivax as Reality
J. Kevin Baird*
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Centre for Tropical Medicine,
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

The report by Quispe and others1 in this issue of the
American Journal of Tropical Medicine and Hygiene adds
to the substantial and growing body of evidence that a diagnosis of Plasmodium vivax malaria often occurs with serious
and threatening illness. The retrospective study by Quispe
and others1 of malaria admissions to a hospital in coastal Peru
comes with assurance of no confounding by P. falciparum by
virtue of its absence from the region. About one-quarter of
patients were classified as critically ill with severe anemia,
shock, lung injury, renal failure, and cerebral syndromes, and
two patients (about 8% of the critically ill) did not survive. Essentially similar rates and findings have come from numerous
hospital-based studies from all across the global reach of
endemic vivax malaria transmission.2 Quispe and others1 express
appropriate caution regarding undiagnosed comorbidities that
may have exacerbated illness in some of those patients.
There is no firm understanding of pathogenesis in vivax
malaria. The roles of comorbidities in serious and fatal disease with a diagnosis of P. vivax require more thorough
investigation than has yet been reported.3 The same issue,
indeed, haunts mortality associated with a diagnosis of falciparum malaria.4 Undiagnosed disease, be it infectious or
not, occurs in relative abundance in rural tropical settings
and may exacerbate or be exacerbated by acute vivax or
falciparum malaria. Real world complexity imposes ambiguities regarding the relationship between threatening illness and the parasite per se. Nonetheless, acceptance of the
reality of vivax malaria as often provoking pernicious and
threatening illness must not await demonstration of the
mechanisms or cofactors. The weight of evidence now available leaves no doubt that vivax malaria in many settings
often occurs in association with a pernicious and threatening
course of illness, which does not assign cause and effect but
instead, acknowledges real consequences without regard to
their specific genesis.
The false aegis of inherent harmlessness in P. vivax
resulted in a 60-year hiatus in biological and clinical research
as well as public health policy and practice.2 We now face a
wide range of very serious gaps in understanding, effective
research, and clinical tools for dealing with this very serious
threat affecting 2.5 billion people.5,6 The dawning understanding of vivax malaria as pernicious and threatening profoundly impacts the management of malaria as both a clinical
and global health problem.
A single entity called the hypnozoite demands a wholly
different approach from conventional P. falciparum-centric

strategic postures in research and practice aimed at malaria.
The hypnozoite of P. vivax completely transforms the landscape of scientific and strategic thinking in the epidemiology,
prevention, control, diagnosis, and treatment of malaria.
An inoculation of P. vivax sporozoites by a single anopheline bite seeds the liver with a brood of hypnozoites. These
hypnozoites remain latent for periods ranging from 3 weeks
to 3 years. When they do emerge, they tend to do so in rapid
succession at intervals of 3 or 4 weeks. At least three relapses
are very common, and up to 20 relapses within 2 years
have been documented. Among cohorts in Thailand and
Indonesia,7–9 the incidence density of first relapse in the
2 months after patency was about five attacks per personyear. African malariologists will recognize that rate as
approximating that by sporozoite-borne P. falciparum in the
most heavily malarious regions.
The hypnozoite in the liver may thus be recognized as
a very significant reservoir of infection of blood. A patient
diagnosed with acute vivax malaria stands at very high risk
of suffering subsequent attacks in quick succession with
deepening risk of serious illness along with opportunities for
transmission to others. Among the many therapies applied
with good safety and efficacy against the acute attack, none
affect the hypnozoite. A single drug kills hypnozoites:
primaquine. This fact—and the ability of primaquine to provoke a potentially lethal acute hemolytic anemia in patients
having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD)—imposes very serious obstacles to successful management of vivax malaria as a clinical and public
health problem.
Quispe and others1 allude to one of the most serious
problems: pregnant women and their infants. A single attack
of vivax malaria in the first trimester of pregnancy elevated
the risk of spontaneous abortion, stillbirth, or low birth weight
by a factor of four.10 Infants were the most vulnerable to
onset of severe anemia associated with acute vivax malaria.11
Pregnant or lactating women and their infants, among the
most vulnerable to serious complications with vivax malaria,
cannot receive primaquine therapy. Despite being exposed
to holoendemic-like attack rates and high risk of very serious
consequences, there has been no work to conceive, evaluate,
optimize, and validate chemotherapeutic or chemopreventive
strategies for pregnant women and infants diagnosed with
P. vivax malaria. The absence of evidence-based guidance
for this serious problem should be considered an urgent global
health problem in need of immediate attention.
Furthermore, most patients diagnosed with G6PD deficiency cannot safely receive primaquine therapy. The World
Health Organization (WHO) recommendation to do so with
eight weekly doses of 45 mg primaquine base does not
come with evidence of safety among the most severe G6PD
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deficiency variants, which happen to be most common where
P. vivax occurs in greatest abundance (south and southeast Asia).12 Finally, a recent study suggests that relatively common mutations to 2D6 cytochrome P-450 leaves
patients partially or fully exposed to risk of relapse, despite
primaquine therapy.13
An accompanying editorial by Price14 regarding a clinical trial of primaquine therapy for vivax malaria in Peru
addresses the even broader problem of the effectiveness of
primaquine therapy in the real world, where G6PD screening
is rarely available and compliance to a 14-day dosing regimen
is quite unlikely. The issues of mortality risk, hypnozoites,
G6PD deficiency, and primaquine therapy all enmesh within
a complex technical weave that may, at first, be difficult to
grasp and understand. Success at doing so, however, illuminates an important raw fact—we have nearly no ability to
mitigate the burden of morbidity and mortality imposed
by the hypnozoite reservoir of P. vivax. The work of Quispe
and others1 serves to further show that this state of affairs
carries very serious consequences.
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